COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc develops novel medicines for the treatment of human viral diseases. It focuses on the development and commercialization of broad-spectrum antiviral drug candidates that transforms the treatment and prophylaxis of diseases in humans.

As of 06/28/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/03/2013
Outstanding shares:  97,469,000
Average volume:  173,640
Market cap:   $37,038,220
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -10.05
PB ratio:   0.50
PS ratio:   0.00
Return on equity:   -16.27%
Net income %:   -220,631.75%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy